VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $207.87 Million Investment in Johnson & Johnson $JNJ

Key Points

• Virginia Retirement Systems purchased 818,463 Johnson & Johnson shares worth approximately $207.9 million, making J&J its 10th-largest holding; institutional investors collectively own 69.55% of the stock.
• Johnson & Johnson exceeded quarterly expectations with $2.90 in adjusted EPS and $25.31 billion in revenue, while revenue rose 6.6% year over year. The company also declared a $1.34 quarterly dividend, equivalent to a 2.0% yield.
• Analysts maintain a generally favorable view, with a consensus “Moderate Buy” rating and a $274.13 price target, while investors weigh potential value from a reported $20 billion DePuy Synthes sale against pipeline setbacks and pricing-related risks.

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 818,463 shares of the company's stock, valued at approximately $207,865,000. Johnson & Johnson makes up approximately 1.2% of VIRGINIA RETIREMENT SYSTEMS ET Al's holdings, making the stock its 10th biggest holding.

Several other institutional investors have also recently made changes to their positions in the company. California State Teachers Retirement System grew its holdings in Johnson & Johnson by 25,103.8% during the 2nd quarter. California State Teachers Retirement System now owns 943,488,645 shares of the company's stock worth $239,617,811,000 after acquiring an additional 939,745,213 shares in the last quarter. Geode Capital Management LLC increased its position in Johnson & Johnson by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company's stock valued at $11,967,947,000 after purchasing an additional 1,738,292 shares during the period. Norges Bank bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $6,924,523,000. Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares during the period. Finally, Deutsche Bank AG boosted its stake in shares of Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company's stock valued at $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $266.81 on Tuesday. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market capitalization of $642.99 billion, a price-to-earnings ratio of 30.92, a PEG ratio of 2.54 and a beta of 0.24. The stock's 50-day simple moving average is $263.18 and its 200-day simple moving average is $246.08.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson's revenue was up 6.6% on a year-over-year basis. During the same period last year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by corporate insiders.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J is reportedly in discussions with Apollo Global Management to sell its DePuy Synthes orthopedics business for approximately $20 billion. A transaction could unlock significant value, provide capital for debt reduction, buybacks or acquisitions, and sharpen the company’s focus on higher-growth businesses. However, DePuy Synthes generated $9.3 billion in sales last year, so investors will weigh proceeds against the loss of ongoing revenue. J&J in talks to sell DePuy Synthes to Apollo for $20 billion
• Positive Sentiment: Phase 3 PAPILLON results for RYBREVANT plus chemotherapy showed median overall survival of 34.3 months in patients with EGFR exon 20 insertion-positive non-small cell lung cancer. The durable benefit strengthens the commercial outlook for a key oncology product and supports J&J’s strategy of offsetting pressure from older medicines. RYBREVANT PAPILLON study results
• Positive Sentiment: Management is targeting double-digit growth despite anticipated biosimilar competition for STELARA, suggesting confidence in new product launches, oncology momentum and broader pharmaceutical diversification. Johnson & Johnson targets double-digit growth
• Neutral Sentiment: At the Morgan Stanley healthcare conference, J&J presented its business outlook and strategy; the available report provides no specific new guidance likely to materially change earnings expectations. Morgan Stanley healthcare conference transcript
• Negative Sentiment: Contineum Therapeutics said the mid-stage trial of JNJ-5120, or PIPE-307, failed to meet its primary objective in major depressive disorder. The failure removes or delays a potential pipeline opportunity, though the financial impact may be limited because the program is partnered. Contineum and J&J depression drug trial
• Negative Sentiment: J&J’s requirement that providers submit claims data to receive 340B discounts could generate pushback from hospitals and safety-net providers, increasing reputational, legal or policy risk around the company’s pricing practices. J&J 340B reporting requirement

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Johnson Rice reissued a "buy" rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Royal Bank Of Canada increased their target price on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Wall Street Zen downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Bank of America boosted their price target on Johnson & Johnson from $254.00 to $263.00 and gave the stock a "neutral" rating in a research report on Friday, July 10th. Finally, Scotiabank restated an "outperform" rating and set a $305.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $274.13.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.